(MedPage Today) — TORONTO — An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta plaques associated with Alzheimer’s disease, performed so well in a phase Ib/IIa trial that pivotal studies…
Source link : https://www.medpagetoday.com/meetingcoverage/aaic/116705
Author :
Publish date : 2025-07-28 20:36:00
Copyright for syndicated content belongs to the linked Source.
